ATHA
Athira Pharma, Inc. Common Stock
stock NASDAQ

Fellow degen,
Tired of randomly picking penny stocks and waiting months to watch them bleed out slowly? What if you could pinpoint the EXACT DATE your position will either moon or crater to zero?
I built [CatalystAlert.io](https://catalystalert.io) \- basically a calendar of binary events for biotech stocks. PDUFA dates, Phase 2/3 data readouts, FDA decisions. You know, the days where your $500 YOLO becomes either $5,000 or $50.
# Q1 2026 Penny Stock Gambling Menu
I pulled the data for companies under $500M market cap with upcoming catalysts. Here's your menu for maximum portfolio destruction:
# 🎰 PDUFA DATES (FDA Says Yes or No - Literally a Coin Flip)
|Date|Ticker|Market Cap|What's Happening|
|:-|:-|:-|:-|
|Jan 31|AQST|$207M|Anaphylm - epinephrine film for anaphylaxis|
|Feb 9|FBIOP|$49M|CUTX-101 for Wilson's disease|
|Feb 17|ALDX|$192M|Reproxalap for dry eye|
|Feb 26|PGEN|$240M|PRGN-3005 gene therapy (Priority Review)|
|Mar 1|OTLK|$180M|LYTENAVA for wet AMD|
|Mar 25|ATHA|$86M|ATH-1017 for Alzheimer's|
|Mar 30|OMER|$225M|OMIDRIA for eye surgery|
**FBIOP at $49M market cap** getting a PDUFA decision in February. That's the kind of asymmetric risk we live for. Or die for. Probably die.
# 🧪 PHASE 3 READOUTS (Positive = 100%+, Negative = -80%)
|Date|Ticker|Market Cap|Drug|Indication|
|:-|:-|:-|:-|:-|
|Jan 15|PVLA|$9M|QTORIN|Lymphatic Malformation|
|Jan 31|KOD|$76M|Tarcocimab|Diabetic Retinopathy|
|Feb 15|CMPS|$355M|Psilocybin|Treatment Resistant Depression|
|Mar 10|SBFM|$23M|Clifutinib|Leukemia|
|Mar 15|KPTI|$108M|Selinexor|Multiple Myeloma|
**PVLA at $9M market cap** with Phase 3 data Jan 15. That's not a stock, that's a lottery ticket with extra steps.
# 💀 MICRO CAP DEGEN SPECIALS (< $100M)
For those who find regular penny stocks too safe:
|Date|Ticker|Market Cap|Event|What Could Go Wrong|
|:-|:-|:-|:-|:-|
|Jan 15|ODYY|**$2M**|Phase 2|Ulcerative Colitis|
|Jan 15|PVLA|$9M|Phase 3|Lymphatic Malformation|
|Jan 15|TRAW|$10M|Phase 2|Endometrial Cancer|
|Feb 1|CNSP|$9M|Phase 2|Glioblastoma|
|Feb 9|FBIOP|$49M|PDUFA|Wilson's Disease|
|Feb 15|GNPX|**$5M**|Phase 2|Lung Cancer|
|Mar 10|SBFM|$23M|Phase 3|Leukemia|
**ODYY at $2M market cap.** That's not even a company, that's three guys in a garage with a dream and your money.
# The Numbers
* **43 catalysts** in Q1 2026
* **12 PDUFA dates** (FDA decisions)
* **10 Phase 3 readouts**
* **21 Phase 2 readouts**
* **16 micro caps** under $100M
# What the site does
* Calendar view of all upcoming biotech catalysts
* Filter by market cap, catalyst type, date
* Company pages with drug pipeline info
* Push notifications so you don't miss your scheduled financial destruction
* ML predictions that are probably wrong (we're in beta, still calibrating our "expected returns" which currently look way too optimistic)
# Why I built this
Because I got tired of finding out about PDUFA dates the day AFTER my bags either mooned or imploded. Now I can plan my disappointment in advance.
**Link:** [catalystalert.io](https://catalystalert.io)
Still in beta. Premium is free right now. The predictions are optimistic and we're working on making them less wrong.
If you spot bad data or missing catalysts, lmk - DM here, [info@catalystalert.io](mailto:info@catalystalert.io), or @catalystalert on Twitter.
*This is not financial advice. This is a tool to help you make terrible decisions more efficiently. Do your own DD. Or don't. I'm not your dad.*
🚀 or 💀 no in between

With Q1 2026 already underway, here's a comprehensive look at the major biotech catalysts coming up over the next \~3 months. This post covers FDA decision dates, Phase 3 data readouts, and key events to watch.
# Quick Stats for Q1 2026
|Category|Count|
|:-|:-|
|PDUFA Dates|26|
|Phase 3 Readouts|68|
|Phase 2 Readouts|97|
|**Total Catalysts**|**192**|
# January 2026 PDUFA Dates
# January 13 - TVTX (Travere Therapeutics) - $620M
**Sparsentan** for IgA nephropathy (Priority Review)
# January 31 - AQST (Aquestive Therapeutics) - $210M
**Anaphylm** \- Epinephrine sublingual film for emergency treatment of anaphylaxis (Priority Review)
# February 2026 PDUFA Dates
|Date|Ticker|Drug|Indication|Review|
|:-|:-|:-|:-|:-|
|Feb 1|VNDA|Investigational drug|Depressive disorder|Standard|
|Feb 8|RGNX|RGX-121|Hunter syndrome (MPS II)|Priority|
|Feb 9|FBIOP|CUTX-101|Wilson's disease|Standard|
|Feb 10|AQST|AQST-109|Epinephrine nasal spray|Standard|
|Feb 12|JAZZ|JZP-458|Acute Lymphoblastic Leukemia|Priority|
|Feb 15|BHVN|\-|\-|\-|
|Feb 17|ALDX|Reproxalap|Dry eye disease|Standard|
|Feb 18|CORT|CORT125134|Cushing's syndrome|Standard|
|Feb 21|SAN.PA|Iniparib|Metastatic breast cancer|Priority|
|Feb 25|ASND|TransCon hGH|Pediatric growth hormone deficiency|Standard|
|Feb 26|PGEN|PRGN-3005|Advanced solid tumors|Priority|
|Feb 28|CRNX|Paltusotine|Acromegaly|Standard|
# Notable February Decisions
**JAZZ (Jazz Pharmaceuticals) - $6.4B market cap** \- JZP-458 for ALL could be significant given Jazz's existing oncology portfolio.
**CRNX (Crinetics) - $3.5B market cap** \- Paltusotine for acromegaly is an oral therapy that could disrupt the injectable-dominated market.
**CORT (Corcept) - $2.7B market cap** \- Second-gen Cushing's treatment with potential to expand their franchise.
# March 2026 PDUFA Dates
|Date|Ticker|Drug|Indication|Review|
|:-|:-|:-|:-|:-|
|Mar 1|SAN.PA|Efanesoctocog alfa|Hemophilia A|Priority|
|Mar 1|OTLK|ONS-5010 / LYTENAVA|Wet AMD|Standard|
|Mar 14|RYTM|IMCIVREE|Obesity (POMC/PCSK1/LEPR deficiency)|Priority|
|Mar 17|ALDX|Reproxalap|Dry eye disease|Standard|
|Mar 18|TVTX|Sparsentan|FSGS and IgA nephropathy|Priority|
|Mar 23|OTLK|ONS-5010|Wet AMD|Standard|
|Mar 25|ATHA|ATH-1017|Alzheimer's disease|Standard|
|Mar 26|GN.CO|Tisotumab vedotin|Cervical cancer|Priority|
|Mar 27|IONS|Inotersen|Transthyretin amyloidosis|Standard|
|Mar 29|LNTH|LNTH-2501|Prostate cancer imaging|Priority|
|Mar 30|OMER|OMIDRIA|Ophthalmic surgery|Standard|
|Mar 31|LENZ|LENZ-123|Alzheimer's disease|Standard|
# Notable March Decisions
**RYTM (Rhythm Pharma) - $7.4B market cap** \- IMCIVREE label expansion for rare obesity disorders. Already approved, seeking broader indications.
**LNTH (Lantheus) - $4.2B market cap** \- LNTH-2501 is their next-gen PSMA imaging agent, following success of Pylarify.
**IONS (Ionis) - $5.7B market cap** \- Inotersen for TTR amyloidosis adds to their antisense oligonucleotide portfolio.
# Major Phase 3 Data Readouts
# January 2026
|Date|Ticker|Drug|Indication|Market Cap|
|:-|:-|:-|:-|:-|
|Jan 12|MRK|Pembrolizumab|NSCLC|$245.9B|
|Jan 15|TBPH|TD-8236|Asthma|$330M|
|Jan 15|TBPH|Ampreloxetine|Neurogenic Orthostatic Hypotension|$330M|
|Jan 19|AZN|Tozorakimab|COPD|\-|
|Jan 27|ROCHE|Fenebrutinib|Relapsing Multiple Sclerosis|\-|
|Jan 30|MRTX|MRTX849 (Adagrasib)|Advanced Cancer|\-|
|Jan 31|KOD|Tarcocimab|Diabetic Retinopathy|$76M|
# February 2026
|Date|Ticker|Drug|Indication|Market Cap|
|:-|:-|:-|:-|:-|
|Feb 3|UCBJY|Bimekizumab|Chronic Plaque Psoriasis|\-|
|Feb 15|CMPS|Psilocybin|Treatment Resistant Depression|$350M|
|Feb 15|DAWN|Tovorafenib|Low-grade Glioma|$970M|
|Feb 15|AVDL|FT218|Narcolepsy|$1.3B|
|Feb 18|PFE|Talazoparib + Enzalutamide|Prostate Cancer|$142.7B|
|Feb 20|NVO|Semaglutide|Obesity|\-|
|Feb 20|NVO|Cagrilintide|Obesity|\-|
|Feb 25|INCY|Povorcitinib|Vitiligo|$9.9B|
# March 2026
|Date|Ticker|Drug|Indication|Market Cap|
|:-|:-|:-|:-|:-|
|Mar 5|MRK|Pembrolizumab|NSCLC|$245.9B|
|Mar 11|ARGX|Efgartigimod|POTS|\-|
|Mar 14|INSM|Treprostinil Palmitil|Pulmonary Hypertension|$11.0B|
|Mar 15|NBIX|Valbenazine|Tardive Dyskinesia|$10.5B|
|Mar 15|MDGL|Resmetirom|NASH|$5.1B|
|Mar 15|LLY|Orforglipron|Obesity|$769.8B|
|Mar 15|RNA|AOC 1001 (del-desiran)|DM1|$10.8B|
|Mar 15|KRYS|KB801|Neurotrophic Keratitis|$4.6B|
|Mar 22|PFE|Ritlecitinib|Vitiligo|$142.7B|
|Mar 27|MLTX|Sonelokimab|Hidradenitis Suppurativa|$1.1B|
|Mar 31|URGN|UGN-104|Upper Tract Urothelial Carcinoma|$680M|
# Key Phase 2 Readouts to Watch
# High Market Cap Companies
* **Jan 15 - LLY ($770B)** \- Tirzepatide for overweight (Phase 2 dose-finding)
* **Jan 17 - REGN ($114B)** \- Vonsetamig for CKD
* **Jan 28 - REGN ($114B)** \- REGN7544 for POTS
* **Jan 31 - MRNA ($42B)** \- mRNA-3927 for Propionic Acidemia
* **Feb 1 - REGN ($114B)** \- Multiple readouts (Sarilumab, Cemiplimab, Tocilizumab)
# Smaller Cap Movers
* **Jan 15 - ANAB ($490M)** \- Rosnilimab for Rheumatoid Arthritis
* **Jan 15 - TNGX ($860M)** \- TNG260 for NSCLC
* **Jan 15 - FDMT ($1B)** \- 4D-310 for Fabry Disease
* **Jan 31 - CGEM ($1B)** \- CLN-081 for NSCLC
# Conference
# January 12-15 - JPM Healthcare Conference 2026
The biggest healthcare investor conference of the year. Expect pipeline updates, M&A rumors, and guidance from major players.
# Top Companies by Catalyst Count (Q1 2026)
|Ticker|Company|Catalysts|Market Cap|
|:-|:-|:-|:-|
|PFE|Pfizer|12|$142.7B|
|REGN|Regeneron|10|$113.8B|
|INCY|Incyte|6|$9.9B|
|LLY|Eli Lilly|4|$769.8B|
|MRK|Merck|4|$245.9B|
# Disclaimer & Data Source
All data in this post comes from [CatalystAlert.io](https://catalystalert.io), a biotech catalyst tracking platform that I built.
**I'm the creator of this platform and we're currently in beta.** Premium features are completely free during the beta period.
If you spot any errors, incorrect dates, or missing catalysts, I'd really appreciate the feedback:
* **DM me** on Reddit
* **Email:** [info@catalystalert.io](mailto:info@catalystalert.io)
* **Twitter/X:** [@catalystalert](https://twitter.com/catalystalert)
We aggregate data from SEC filings, FDA, ClinicalTrials.gov, and other public sources. Accuracy matters to us, so any corrections help improve the platform for everyone.
*Not financial advice. Do your own DD. Dates are subject to change based on FDA/company decisions.*

ATHA Energy Corp